Prostate cancer that has spread to other parts of the body has limited treatment options, but a biomedical research group affiliated with Main Line Health has begun investigating a new therapy for ...

The U.S. Food and Drug Administration (FDA) approved six new therapies in December 2025 for blood cancers, prostate cancer, ...

In men with newly diagnosed metastatic hormone-sensitive prostate cancer, adding lutetium-177 PSMA-617 (177 Lu-PSMA-617) to standard hormone therapy led to a statistically significant improvement in ...

Researchers have discovered that prostate cancer depends on two key enzymes, PDIA1 and PDIA5, to survive and resist therapy. When blocked, these enzymes cause the androgen receptor to collapse, ...

A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that that combining pembrolizumab, an immunotherapy drug, with standard chemotherapy can improve ...

Please provide your email address to receive an email when new articles are posted on . You've successfully added to your alerts. You will receive an email when new content is published. Click Here to ...

A major international study has uncovered a new vulnerability in prostate cancer cells that could help improve treatment for one of the most common cancers affecting men. The research, published in ...

Here are the top 5 stories from 2025 about the advancements in prostate, kidney, and bladder cancers.